Cardioprotection thread, page-674

It's really not that hard to find for someone of adequate skill.

Below is a systematic review of oncolytic viruses from 2020, which includes 86 clinical trials - 60, of which, are phase 1. Gee, I wonder why there aren't many P2s relative to P1s. Imagine doubling and tripling down on a product joining a loooong list of failures when you could have made bank like management and Fong did.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589713/

There have been 8 phase II trials investigating Bisantrene as a single agent at a 250 mg/m2 7-day regimen, with an average weighted CR rate of 50.7%. I've attached the 7 PDFs that are available with the other paper quoted in three of the papers.



Spadea 1993_P2 Bisantrene in relapsed refractory AML.pdf
Canaai 2020_P2 AML.pdf
Bezwoda 1989_Bisantrene in ANLL.pdf
Fenaux 1991_P2 Bisantrene as salvage Tx.pdf
Isnard 1987_P2 bisantrene in relapsing or refractory leukemia.pdf
Marty 1984_Bisantrene P2 in ANLL0001.pdf
Tosi 1989_P2 bisantrene in ANLL.pdf

Here is how that data compares to approved therapies in the same patient populations. Note: Bisantrene is a first-in-class CPACS drug that modulates m6A levels through the inhibition of FTO, which is also a first-in-class. The clinical competitors are 0 as are the commercial competitors.



Here is a P1 trial of Bisantrene that you should probably look at. Have you ever thought you don't understand Bisantrene because you don't know what good looks like? 35% ORR in this P1 is the same response rate quoted on the FDA label for Doxorubicin

Marty 1985_ANLL (AML) P1.pdf

Now, show me a cardioprotective anti-cancer agent.